2101 - 2125 of 9037 Results
Title
Year
-
OPENTitle: Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammationJournal Name: Mucosal ImmunologyPublisher: Elsevier BVVol: 14Issue #: 3Start Page: 652End Page: 666Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41385-020-00354-7Best OA location URL: https://www.nature.com/articles/s41385-020-00354-7.pdfCitation Count: 40
-
OPENTitle: The effects of mood and cognition on daily functioning and quality of life in older people living with HIV and people with Parkinson’s disease.Journal Name: NeuropsychologyPublisher: American Psychological Association (APA)Vol: 35Issue #: 7Start Page: 691End Page: 705Publication Date:Open Access(OA) Status: OPENLicense: other-oaDOI - Digital Object Identifier: 10.1037/neu0000760Best OA location URL: https://doi.org/10.1037/neu0000760Citation Count: 3
- Dynamic interplay of cognitive functioning and depressive symptoms in patients with Parkinson’s disease.2022RESTRICTEDTitle: Dynamic interplay of cognitive functioning and depressive symptoms in patients with Parkinson’s disease.Journal Name: NeuropsychologyPublisher: American Psychological Association (APA)Vol: 36Issue #: 4Start Page: 266End Page: 278Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1037/neu0000795Citation Count: 5
-
OPENTitle: Allosteric Inhibition of Parkinson’s-Linked LRRK2 by Constrained PeptidesJournal Name: ACS Chemical BiologyPublisher: American Chemical Society (ACS)Vol: 16Issue #: 11Start Page: 2326End Page: 2338Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1021/acschembio.1c00487Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acschembio.1c00487Citation Count: 40
- Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation2022OPENTitle: Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and DifferentiationJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 13Issue #: 23Start Page: 3281End Page: 3290Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acschemneuro.2c00342Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/12316044Citation Count: 21
- Structure–Functional Selectivity Relationship Studies on A-86929 Analogs and Small Aryl Fragments toward the Discovery of Biased Dopamine D1 Receptor Agonists2022RESTRICTEDTitle: Structure–Functional Selectivity Relationship Studies on A-86929 Analogs and Small Aryl Fragments toward the Discovery of Biased Dopamine D1 Receptor AgonistsJournal Name: ACS Chemical NeurosciencePublisher: American Chemical Society (ACS)Vol: 13Issue #: 12Start Page: 1818End Page: 1831Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acschemneuro.2c00235Citation Count: 4
-
OPENTitle: Metabolic Profiling of Neocortical Tissue Discriminates Alzheimer’s Disease from Mild Cognitive Impairment, High Pathology Controls, and Normal ControlsJournal Name: Journal of Proteome ResearchPublisher: American Chemical Society (ACS)Vol: 20Issue #: 9Start Page: 4303End Page: 4317Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acs.jproteome.1c00290Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/11060066Citation Count: 48
- Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease2022OPENTitle: Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s DiseaseJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 65Issue #: 24Start Page: 16801End Page: 16817Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acs.jmedchem.2c01605Citation Count: 24
- A Comparative Study of High-Contrast Fluorescence Lifetime Probes for Imaging Amyloid in Tissue2021OPENTitle: A Comparative Study of High-Contrast Fluorescence Lifetime Probes for Imaging Amyloid in TissueJournal Name: The Journal of Physical Chemistry BPublisher: American Chemical Society (ACS)Vol: 125Issue #: 50Start Page: 13710End Page: 13717Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/acs.jpcb.1c07762Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7615715Citation Count: 9
- PINK1/Parkin-Mediated Mitophagy Plays a Protective Role in the Bone Impairment Caused by Aluminum Exposure2021RESTRICTEDTitle: PINK1/Parkin-Mediated Mitophagy Plays a Protective Role in the Bone Impairment Caused by Aluminum ExposureJournal Name: Journal of Agricultural and Food ChemistryPublisher: American Chemical Society (ACS)Vol: 69Issue #: 21Start Page: 6054End Page: 6063Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.jafc.1c01921Citation Count: 29
-
OPENTitle: Native Separation and Metallation Analysis of SOD1 Protein from the Human Central Nervous System: a Methodological WorkflowJournal Name: Analytical ChemistryPublisher: American Chemical Society (ACS)Vol: 93Issue #: 32Start Page: 11108End Page: 11115Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1021/acs.analchem.1c01128Best OA location URL: https://pubs.acs.org/doi/pdf/10.1021/acs.analchem.1c01128Citation Count: 8
-
OPENTitle: Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and BallismusJournal Name: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences NeurologiquesPublisher: Cambridge University Press (CUP)Vol: 49Issue #: 3Start Page: 431End Page: 432Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1017/cjn.2021.136Citation Count: 3
-
OPENTitle: The Records of the Human Sciences Research CouncilJournal Name: History in AfricaPublisher: Cambridge University Press (CUP)Vol: 48Issue #:Start Page: 397End Page: 411Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1017/hia.2021.15Citation Count: 1
-
OPENTitle: Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learningJournal Name: The Lancet Digital HealthPublisher: Elsevier BVVol: 3Issue #: 9Start Page: e555End Page: e564Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/s2589-7500(21)00101-1Best OA location URL: http://www.thelancet.com/article/S2589750021001011/pdfCitation Count: 89
-
OPENTitle: Artificial intelligence for detection of Alzheimer's disease: demonstration of real-world value is required to bridge the translational gapJournal Name: The Lancet Digital HealthPublisher: Elsevier BVVol: 4Issue #: 11Start Page: e768End Page: e769Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/s2589-7500(22)00190-xBest OA location URL: http://www.thelancet.com/article/S258975002200190X/pdfCitation Count: 4
-
OPENTitle: Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 203End Page: 212Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30449-xBest OA location URL: http://hdl.handle.net/2445/214932Citation Count: 331
-
OPENTitle: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 182End Page: 192Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30489-0Best OA location URL: http://www.thelancet.com/article/S1474442220304890/pdfCitation Count: 137
-
OPENTitle: Prehospital scales in acute ischaemic stroke management – Authors' replyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 504End Page: 505Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00169-1Best OA location URL: https://pure.eur.nl/en/publications/25abb6f2-0472-4754-8580-97e2533ac37aCitation Count: 1
- Freezing of gait and levodopa2021OPENTitle: Freezing of gait and levodopaJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 505End Page: 506Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00175-7Citation Count: 8
- Movement disorders research in 2021: cracking the paradigm2021RESTRICTEDTitle: Movement disorders research in 2021: cracking the paradigmJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 1Start Page: 10End Page: 11Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00413-0Citation Count: 19
- Amantadine in the treatment of Parkinson's disease and other movement disorders2021RESTRICTEDTitle: Amantadine in the treatment of Parkinson's disease and other movement disordersJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 12Start Page: 1048End Page: 1056Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00249-0Citation Count: 198
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial2022RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 204
- The East Asian Parkinson Disease Genomics Consortium2021OPENTitle: The East Asian Parkinson Disease Genomics ConsortiumJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 12Start Page: 982End Page: 982Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00373-2Citation Count: 9
- Major advances in Parkinson's disease over the past two decades and future research directions2022RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 18
- Revisiting levodopa for advanced Parkinson's disease2022RESTRICTEDTitle: Revisiting levodopa for advanced Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1063End Page: 1065Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5Citation Count: 2